FIGURE SUMMARY
Title

Amino acid modified OCMC-g-Suc-β-CD nanohydrogels carrying lapatinib and ginsenoside Rg1 exhibit high anticancer activity in a zebrafish model

Authors
Cui, L., Liu, X., Yan, R., Chen, Q., Wang, L., Nawaz, S., Qin, D., Wang, D.
Source
Full text @ Front Pharmacol
FIGURE 1

Preparation of amino acid modified OCMC-g-Suc-β-CD nanohydrogels carrying anticancer drug.
FIGURE 2

(A) FTIR spectra of β-CD and Suc-β-CD; (B) FTIR spectra of OCMC-g-Suc-β-CD, L-His-OCMC-g-Suc-β-CD, and L-Arg-OCMC-g-Suc-β-CD; TEM images of (C)L-His-OCMC-g-Suc-β-CD and (D)L-Arg-OCMC-g-Suc-β-CD.
FIGURE 3

Particle size distribution of (A)L-His-OCMC-g-Suc-β-CD and (B)L-Arg-OCMC-g-Suc-β-CD; (C) Particle sizes and PDI of (a) L-His-OCMC-g-Suc-β-CD and (b) L-Arg-OCMC-g-Suc-β-CD.
FIGURE 4

Drug release behavior of nanohydrogels 1-4 under (A) pH = 7.4 and (B) pH = 4.5; Drug release behavior of nanohydrogels (C) 5 and (D) 6.
FIGURE 5

In vitro cytotoxicity of amino acid modified OCMC-g-Suc-β-CD nanohydrogels 1-6 carrying anticancer drugs against A549 cells after incubation for 48 h. Nanohydrogels 1: L-His-OCMC-g-Suc-β-CD carrying Lapatinib; nanohydrogels 2: L-His-OCMC-g-Suc-β-CD carrying ginsenoside Rg1; nanohydrogels 3: L-Arg-OCMC-g-Suc-β-CD carrying lapatinib; nanohydrogels 4: L-Arg-OCMC-g-Suc-β-CD carrying ginsenoside Rg1; nanohydrogels 5: L-His-OCMC-g-Suc-β-CD carrying lapatinib and ginsenoside Rg1; nanohydrogels 6: L-Arg-OCMC-g-Suc-β-CD carrying lapatinib and ginsenoside Rg1. The experiments were repeated 3 times, each with n = 3 per group. The data were presented as mean ± SEM and analyzed by one-way ANOVA followed by Dunett’s test using Graph Pad Prism 6.01 software. *p < 0.05, **p < 0.01, ***p < 0.001 VS. 0 µg/mL for each group.
FIGURE 6

Images of zebrafish (A) and fluorescence intensity in zebrafish liver (B) exposed to Doxc (25 μg/mL) and tested compounds including lapatinib (4 µg/mL), ginsenoside Rg1 (4 µg/mL), nanohydrogels 5 (the concentration of lapatinib plus ginsenoside Rg1 1, 2, and 4 µg/mL), and nanohydrogels 6 (the concentration of lapatinib plus ginsenoside Rg1 was 1, 2, and 4 µg/mL). Scale bar is 500 μm. Data were analyzed by one-way ANOVA followed by Dunett’s test using a Graph Pad Prism 6.01 software. The results were expressed as mean ± SEM, **p < 0.01, ***p < 0.001 VS. Doxc.
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Front Pharmacol
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.